Imaging as a methodological pillar in oncology development.
In oncology, imaging is not merely a diagnostic tool: it is a regulatory endpoint, a surrogate biomarker and, increasingly, a key factor in decision-making throughout clinical development.
Oncological endpoints demand control of variability.
Oncological studies are built on imaging-centred endpoints. Applying criteria such as RECIST, iRECIST or criteria specific to solid and rare tumours introduces inter-observer and inter-centre variability that must be controlled through structured processes.
Even minimal discrepancies in the measurement of target lesions can significantly influence the primary statistical analysis.
Our approach rests on a rigorously defined imaging charter, pre-calibration of reviewers, independent central review and a comprehensive, traceable audit trail — reducing statistical dispersion and strengthening the robustness of primary and secondary endpoints.
See our approach
An approach built for endpoint robustness.
From the imaging charter to the final read, every step is designed to control variability — aligning reviewers, sequencing reviews and tracing each decision so oncology endpoints stay reproducible and defensible.
- Imaging charter. Acquisition, criteria and lesion rules defined before first patient in.
- Reviewer pre-calibration. Reviewers aligned to RECIST / iRECIST and study-specific criteria.
- Independent central review. Blinded reads that protect the integrity of the endpoint.
- Traceable audit trail. Every measurement and decision documented end to end.
- Reduced dispersion. Lower inter-observer variability strengthens the primary analysis.
Illustrative interface — sample data, not client results.
Functional biomarkers, standardised across sites.
Modern oncology integrates morphological and functional imaging. We harmonise these methods across centres to avoid systematic bias and preserve the reliability of quantitative biomarkers in global studies.
PET metabolism
Metabolic activity quantified to characterise tumour behaviour and treatment effect.
Diffusion-weighted MRI
Cell density assessed through diffusion to track structural tumour change.
Dynamic imaging
Perfusion and vascular dynamics measured to probe the tumour microenvironment.
Early response
Functional signals that surface treatment response before morphological change.
Cross-site harmonisation
Standardisation strategies that keep quantitative reads comparable across platforms and centres.
Imaging at the centre of targeted therapies.
Our expertise combines molecular imaging and clinical dosimetry to support early-phase and pivotal studies.
With the growth of radiolabelled and targeted treatments, imaging takes on an even more strategic role in oncology development.
For oncological radiopharmaceuticals, imaging is integral to demonstrating biological targeting, assessing biodistribution, performing dosimetric analysis and stratifying patients.
These studies are also frequently multicentre and international — spanning many sites, heterogeneous platforms and populations under tight deadlines. We manage that complexity through rigorous site qualification, continuous quality monitoring, independent centralised review and archiving aligned with international regulations.
Oncology imaging needs a scientific partner.
Oncology imaging cannot be left to technical improvisation. It must be designed, monitored and analysed with methodological rigour.
-
Study direction
Imaging decisions can drive the continuation or discontinuation of the study.
-
Patient stratification
Functional and molecular imaging informs how patients are stratified.
-
Regulatory credibility
Consistent, reproducible imaging data underpins the strength of the dossier.
-
Inspection-ready
An independent partner keeps imaging defensible during inspections.
Bring methodological rigour to your oncology imaging.
Discover how a structured, independent imaging methodology can strengthen the endpoints of your oncology study.